Mammoth Biosciences
PrivateLast Round
Series D
Sep 9, 2021
Est. Valuation
$1B
Total Funding Raised
$287.6M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Mammoth Biosciences operates in Healthcare & Life Sciences and is based in Brisbane, California. Its latest recorded funding round was a Series D round in September 2021.
Mammoth Biosciences is a biotechnology company that develops long-term curative therapies and decentralized precision diagnostics using proprietary ultracompact CRISPR proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical Devices
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mammoth Biosciences Comparables
Compare Mammoth Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Metagenomi | 85% | |
| Arbor Biotechnologies | 82% | |
| Scribe Therapeutics | 77% |
For institutional investors. Book with your work email.
Mammoth Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 9, 2021 | ||||
| Series C | Nov 1, 2020 | ||||
| Grant | Jul 30, 2020 | ||||
| Series B | Jan 30, 2020 | ||||
| Series A | Jul 31, 2018 | ||||
Seed | Nov 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mammoth Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series D |
| NFX | Series A, Series B, Series D, Seed, Pre Seed |
| Pacific 8 Ventures | Series B |
| NIH RADx | Grant |
| Plum Alley Investments | Series B |
| StepStone Group | Series D |
| Sixth Street Partners | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2026
Partnered with New England Biolabs for assay development.
- Nov 10, 2026
MB-CasFire launched in partnership with New England Biolabs.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesNov 10, 2026
Mammoth launches MB-CasFire(TM) commercially with New England Biolabs in Massachusetts on Nov 10th '26, making the proprietary CRISPR enzyme available for Research Use Only to support one-pot isothermal amplification assay development.
- licenses_technologyNov 10, 2026
On Nov 10th '26 in Massachusetts, Mammoth licenses its proprietary MB-CasFire enzyme to New England Biolabs, Inc. under a global agreement under which New England Biolabs, Inc. is to manufacture and commercialize the enzyme for Research Use Only.
For institutional investors. Book with your work email.
Mammoth Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mammoth Biosciences's valuation, stock price, and market status.
Is Mammoth Biosciences a public or private company?
Mammoth Biosciences is a private company.
What is the current stock price of Mammoth Biosciences?
Mammoth Biosciences is a private company, so its shares have no public market price. Caplight tracks Mammoth Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mammoth Biosciences worth (valuation)?
Mammoth Biosciences's valuation is estimated at $1.0B based on funding round data.
Can I buy Mammoth Biosciences stock?
Mammoth Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mammoth Biosciences's last funding round?
Mammoth Biosciences's most recent funding round was Series D on September 9, 2021.
Who are the main investors in Mammoth Biosciences?
Key investors in Mammoth Biosciences include Redmile Group, NFX, Foresite Capital, Decheng Capital, Mayfield Fund.
Will Mammoth Biosciences IPO soon?
No public IPO plans have been announced for Mammoth Biosciences.
How can I track Mammoth Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Mammoth Biosciences's shares on secondary markets.